Resistance to anti-platelet agents

Thrombosis Research

Volumn 127, Issue SUPPL. 3, 2011, Pages

  Cattaneo, Marco ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Antiplatelet agents; Aspirin; Clopidogrel; Drug resistance; P2Y12; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYCLOOXYGENASE 1; MULTIDRUG RESISTANCE PROTEIN 1; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; THIENOPYRIDINE DERIVATIVE; THROMBOXANE A2; THROMBOXANE B2; TICAGRELOR;

ADD ON THERAPY; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG TREATMENT FAILURE; GENE MUTATION; HUMAN; LABORATORY TEST; LOADING DRUG DOSE; PHARMACOGENETICS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THROMBOCYTE FUNCTION; TREATMENT RESPONSE;

ADENOSINE; ASPIRIN; DRUG RESISTANCE; HUMANS; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; THIOPHENES; TICLOPIDINE;

EID: 79251527877     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(11)70017-2     Document Type: Article

References (27)

1. M Cattaneo Aspirin and clopidogrel. Efficacy, safety and the issue of drug resistance Arterioscler Thromb Vasc Biol 24 2002 1980 1987
2. C Patrono Aspirin resistance: definition, mechanisms and clinical read-outs J Thromb Haemost 1 2003 1710 1713
3. GJ Hankey, JW Eikelboom Aspirin resistance Lancet 367 2006 606 617
4. CL Campbell, SR Steinhubl Variability in response to aspirin: do we understand the clinical relevance? J Thromb Haemost 3 2005 665 669
5. AL Frelinger 3rd, MI Furman, MD Linden, Y Li, ML Fox, MR Barnard Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance Circulation 113 25 2006 2888 2896
6. KA Schwartz, DE Schwartz, K Ghosheh, MJ Reeves, K Barber, A De Franco Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction Am J Cardiol 95 2005 973 975
7. AL Frelinger 3rd, Y Li, MD Linden, MR Barnard, ML Fox, DJ Christie Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization Circulation 120 25 2009 2586 2596
8. M Cattaneo ADP receptors antagonists AD Michelson Platelets 2006 Academic Press San Diego, CA 1127 1144
9. JD Snoep, MM Hovens, JC Eikenboom, JG van der Bom, JW Jukema, MV Huisman Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis Am Heart J 154 2007 221 231
10. JT Brandt, SL Close, SJ Iturria, CD Payne, NA Farid, CS Ernest 2nd Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel J Thromb Haemost 5 2007 2429 2436
11. JS Hulot, A Bura, E Villard, M Azizi, V Remones, C Goyenvalle Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects Blood 108 2006 2244 2247
12. T Simon, C Verstuyft, M Mary-Krause, L Quteineh, E Drouet, N Méneveau French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 2009 363 375
13. JL Mega, SL Close, SD Wiviott, L Shen, JR Walker, T Simon Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis Lancet 2010 Aug 27 [Epub ahead of print].
14. JS Hulot, JP Collet, J Silvain, A Pena, A Bellemain-Appaix, O Barthélémy Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis J Am Coll Cardiol 56 2010 134 143
15. NJ Breet, JW van Werkum, HJ Bouman, JC Kelder, HJ Ruven, ET Bal Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation JAMA 303 2010 754 762
16. T Cuisset, C Frere, R Poyet, J Quilici, B Gaborit, L Bali Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting Arch Cardiovasc Dis 103 2010 39 45
17. T Gremmel, S Steiner, D Seidinger, R Koppensteiner, S Panzer, CW Kopp Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation Thromb Haemost 101 2009 333 339
18. R Paniccia, E Antonucci, N Maggini, M Miranda, AM Gori, R Marcucci Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients Thromb Haemost 104 2 2010 May 10 [Epub ahead of print].
19. IS Kim, YH Jeong, MK Kang, JS Koh, Y Park, SJ Hwang Correlation of high post-treatment platelet reactivity assessed by light transmittance aggregometry and the VerifyNow P2Y(12) assay J Thromb Thrombolysis 2010 May 7 [Epub ahead of print].
20. EH Madsen, J Saw, SR Kristensen, EB Schmidt, C Pittendreigh, E Maurer-Spurej Long-term aspirin and clopidogrel response evaluated by light transmission aggregometry, VerifyNow, and thrombelastography in patients undergoing percutaneous coronary intervention Clin Chem 56 2010 839 847
21. B Aleil, C Léon, JP Cazenave, C Gachet CYP2C19*2 polymorphism is not the sole determinant of the response to clopidogrel: implications for its monitoring J Thromb Haemost 7 2009 1747 1749
22. W Hochholzer, D Trenk, MF Fromm, CM Valina, C Stratz, HP Bestehorn Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement J Am Coll Cardiol 55 2010 2427 2434
23. L Bonello, L Camoin-Jau, S Arques, C Boyer, D Panagides, O Wittenberg Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study J Am Coll Cardiol 51 2008 1404 1411
24. L Bonello, L Camoin-Jau, S Armero, O Com, S Arques, C Burignat-Bonello Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis Am J Cardiol 103 2009 5 10
25. A Pena, JP Collet, JS Hulot, J Silvain, O Barthélémy, F Beygui Can we override clopidogrel resistance? Circulation 119 2009 2854 2857
26. SD Wiviott, E Braunwald, CH McCabe, G Montalescot, W Ruzyllo, S Gottlieb for the TRITON-TIMI 38 Investigators Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015 (Pubitemid 350106708)
27. L Wallentin, RC Becker, A Budaj, CP Cannon, H Emanuelsson, C Held PLATO Investigators, A Freij, M Thorsén Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057